BRONCHICINE CAe is licensed for the vaccination of healthy dogs 8 weeks of age or older as an aid in the control of canine infectious tracheobronchitis (kennel cough) caused by Bordetella bronchiseptica.
BRONCHICINE CAe is a killed cellular antigen extract of the Bordetella bronchiseptica microorganism.
BRONCHICINE CAe is prepared from antigenic material extracted from B. bronchiseptica. An immunogenic strain of B. bronchiseptica is grown to a high yield, then subjected to a proprietary process that extracts the antigens from the B. bronchiseptica cells. The residual cell debris is then removed, resulting in a product that retains the desirable immunologic qualities of a whole cell vaccine, while helping reduce undesirable adverse events (AEs).
BRONCHICINE CAe has sold more doses than any other parenteral B. bronchiseptica vaccine for dogs.1
Bordetella pertussis and B. bronchiseptica are closely related.2
The presence of vaccine-induced serum antibodies is a good correlate of immunity against B. pertussis in children3 and against B. bronchiseptica in dogs.4
Parenterally administered BRONCHICINE CAe vaccine has been demonstrated to have a low rate of AEs associated with administration.
82% of veterinary workers’ compensation claims are from animal bites and scratches.*,5
BRONCHICINE CAe is administered further from the mouth.
Protection beyond the vaccine
The Zoetis Petcare Immunization Support Guarantee†:
Covers diagnostics to establish whether a pet vaccinated with one of the Zoetis vaccine antigens† has contracted the corresponding disease.
If the diagnostics confirm the corresponding disease, the Petcare Immunization Support Guaranteee† will cover physical examination, ancillary diagnostic and therapeutic charges up to a maximum of $5,000.
Includes coverage for up to four years on core antigens and up to one year on most non-core antigens.†